Search results for: Precision Medicine
Filter search results
Moving the Needle on Value – OHE Launches Research on US Value-Based Healthcare
10 June 2019
…been applied almost exclusively to medicines and medical technology. Similarly, there has been significant political and media attention given to the cost of medicines. But, this attention in terms of…
25 Years of the Cost Effectiveness Acceptability Curve
30 December 2019
…the London School of Hygiene and Tropical Medicine spoke at a reception at the ISPOR Europe conference in November to celebrate Ben’s contribution. As 2019 comes to a close, OHE…
Are Cost-Effectiveness Thresholds Fit for Purpose for Real-World Decision Making on Access to and Pricing of Pharmaceuticals? A New OHE Paper on Current Methods and Practices, and a Novel Approach for Optimal Thresholds
3 March 2020
…Institute for Health and Care Excellence (NICE) in the UK) – or implicitly – where a threshold is informally accepted by decision makers (e.g. Canada – before the Patented Medicines…
NICE ‘Optimised’ Recommendations: What Do They Mean for Patient Access?
30 July 2020
…with marketing authorisation), ‘not recommend’ the medicine, or something in between: ‘optimised’. Optimised recommendations support use of the medicine for a smaller group of patients than originally stated by the…
Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?
17 September 2020
…socioeconomic benefits of vaccination. Science Translational Medicine, [online] 10(441). 10.1126/scitranslmed.aaj2345. Brouwer, W.B.F., Koopmanschap, M.A. and Rutten, F.F.H., 1997a. Productivity costs in cost-effectiveness analysis: numerator or denominator: a further discussion. Health…
Collaborating on Payment Models to Unlock the Potential of Multi-Indication Therapies.
22 June 2022, 2:00pm
Innovation in drug development is evolving at pace. Individual medicines are increasingly found to benefit patients in a range of indications within or across diseases, at different stages of disease,…
What is the Role of HTA for Biosimilars?
1 April 2014
…ten experts: leading academics and representatives from the UK medicines regulatory agency, the three… This Briefing summarises the results of a roundtable convened by OHE to discuss using HTA to…
Progress against Tuberculosis
1 October 1962
It is a pleasure to write a short Preface to the first booklet issued by the Office of Health Economic. For too long our attitude to the economics of medicine…
Trade and Price Differentials for Pharmaceuticals: Policy Options
1 May 1997
…as Spain and, in the future, the countries of Eastern Europe. In addition, since 1995 new medicines that are approved by the European Medicines Agency are automatically approved in all…